Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study
文献类型：期刊论文
| 作者 | Cao, Fei3; Shi, Changsheng2; Zhang, Guofu1; Luo, Jun3; Zheng, Jiaping3; Hao, Weiyuan3 |
| 刊名 | BMC CANCER
 |
| 出版日期 | 2023-09-18 |
| 卷号 | 23 |
| 关键词 | Hepatocellular carcinoma Atezolizumab Bevacizumab Overall survival Progression-free survival |
| DOI | 10.1186/s12885-023-11389-x |
| 通讯作者 | Hao, Weiyuan(13820806811@163.com) |
| 英文摘要 | PurposeThe aim of the present study was to assess the efficacy and safety of transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab (hereafter, TACE-Atez/Bev) in the treatment of advanced hepatocellular carcinoma (HCC) patients.Materials and methodsClinical information was collected from consecutive patients with advanced HCC who received treatment with TACE-Atez/Bev or Atez/Bev from April 2021 and October 2022. Treatment response, overall survival (OS), and progression-free survival (PFS) were the primary outcomes of this study. Adverse events (AEs) were the secondary outcomes. Propensity score matching (PSM) analysis was applied to reduce bias between two groups.ResultsThis study included 62 patients in the TACE-Atez/Bev group and 77 patients in the Atez/Bev group. The objective response rate (ORR) of the TACE-Atez/Bev group and the Atez/Bev group were 38.7% and 16.9% (P=0.004). However, there was no statistical difference in disease control rate between the two groups (69.4% vs 63.6%, P=0.479). Before PSM, the median OS was 14 months in the TACE-Atez/Bev group and 10 months in the Atez/Bev group (P=0.014). The median PFS in the TACE-Atez/Bev and Atez/Bev groups was 10 months and 6 months, respectively (P=0.001). After PSM, the median OS in the two groups was 14 months and 9 months, respectively (P=0.01). The median PFS was 7 months and 6 months, respectively (P=0.036). Multivariable analysis showed that treatment method was independent prognostic factors affecting OS.ConclusionsCompared with Atez/Bev treatment, TACE-Atez/Bev showed better OS, PFS, and ORR for Chinese patients with advanced HCC, with an acceptable safety profile. |
| WOS关键词 | RADIOFREQUENCY ABLATION ; LENVATINIB |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| 出版者 | BMC |
| WOS记录号 | WOS:001068000700001 |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/132522]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Hao, Weiyuan |
| 作者单位 | 1.Zhejiang Elderly Care Hosp, Hangzhou 310022, Zhejiang, Peoples R China 2.Wenzhou Med Univ, Dept Intervent, Affiliated Hosp 3, Ruian 325200, Zhejiang, Peoples R China 3.Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC,Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China |
| 推荐引用方式 GB/T 7714 | Cao, Fei,Shi, Changsheng,Zhang, Guofu,et al. Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study[J]. BMC CANCER,2023,23. |
| APA | Cao, Fei,Shi, Changsheng,Zhang, Guofu,Luo, Jun,Zheng, Jiaping,&Hao, Weiyuan.(2023).Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study.BMC CANCER,23. |
| MLA | Cao, Fei,et al."Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study".BMC CANCER 23(2023). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。